Article
Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.
Experimental & molecular medicine - 8 Feb 2013
Park Sung Nam, Noh Kyung Tae, Jeong Young-Il, Jung In Duk, Kang Hyun Kyu, Cha Gil Sun, Lee Su Jung, Seo Jong Keun, Kang Dae Hwan, Hwang Tae-Ho, Lee Eun Kyung, Kwon Byungsuk, Park Yeong-Min
Abstract excerpt
We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1β, tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) production...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
